LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.72 USD | +1.75% |
|
-1.87% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 20.46M | Capitalization | 401M |
|---|---|---|---|---|---|
| Net income 2024 * | -55M | Net income 2025 * | -70M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 19.6 x |
| P/E ratio 2024 * |
-7.19
x | P/E ratio 2025 * |
-6.46
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.75% | ||
| 1 week | -1.87% | ||
| Current month | -29.60% | ||
| 1 month | -27.92% |
1 week
15.05
16.73
1 month
15.0524.59
Current year
15.0524.59
1 year
15.0524.59
3 years
15.0524.59
5 years
15.0524.59
10 years
15.0524.59
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 15.72 | +1.75% | 200,720 |
| 24-04-25 | 15.45 | -2.59% | 171,778 |
| 24-04-24 | 15.86 | -0.38% | 117,177 |
| 24-04-23 | 15.92 | +0.19% | 120,601 |
| 24-04-22 | 15.89 | -0.81% | 123,610 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.72
USD
Average target price
36.75
USD
Spread / Average Target
+133.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 401M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LENZ Stock
